Palisade Bio (NASDAQ:PALI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Palisade Bio (NASDAQ:PALI) from a sell rating to a hold rating in a research report report published on Saturday.

Several other equities analysts have also commented on the company. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Weiss Ratings cut Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. Wolfe Research began coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective for the company. Finally, Oppenheimer initiated coverage on shares of Palisade Bio in a research note on Thursday. They set an “outperform” rating and a $8.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Palisade Bio has an average rating of “Buy” and an average price target of $9.00.

Palisade Bio Stock Performance

Shares of PALI opened at $2.03 on Friday. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $2.85. The company has a market capitalization of $352.37 million, a PE ratio of -2.01 and a beta of 1.50. The stock has a fifty day moving average of $1.93 and a two-hundred day moving average of $1.90.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, equities research analysts forecast that Palisade Bio will post -0.24 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Mitchell Lawrence Jones sold 51,880 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total value of $106,354.00. Following the transaction, the insider directly owned 94,009 shares of the company’s stock, valued at approximately $192,718.45. This trade represents a 35.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera bought 25,000 shares of Palisade Bio stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average price of $1.96 per share, for a total transaction of $49,000.00. Following the acquisition, the director directly owned 461,904 shares of the company’s stock, valued at $905,331.84. The trade was a 5.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 125,000 shares of company stock valued at $250,100 in the last ninety days. Company insiders own 0.07% of the company’s stock.

Institutional Trading of Palisade Bio

A number of institutional investors have recently modified their holdings of PALI. CTC Alternative Strategies Ltd. acquired a new stake in Palisade Bio during the 1st quarter worth approximately $31,000. Bank of America Corp DE lifted its position in Palisade Bio by 181.1% during the first quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock valued at $345,000 after buying an additional 126,977 shares in the last quarter. Janus Henderson Group PLC lifted its position in Palisade Bio by 1.4% during the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock valued at $18,760,000 after buying an additional 149,118 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in Palisade Bio by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock worth $3,963,000 after buying an additional 260,000 shares during the period. Finally, Orbimed Advisors LLC grew its stake in Palisade Bio by 24.7% during the first quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock worth $4,083,000 after buying an additional 461,580 shares during the period. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.